Context Therapeutics Inc. (CNTX)
Context Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Philadelphia, PA, US. The stock last traded at $0.47, up 2.98% on the session, giving a market capitalisation of $42.8M. On trailing twelve-month figures it carries a trailing P/E of -0.97, a net margin of 0.0%. Its beta of 1.75 implies it has historically moved more than the broad market.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics Inc. is most often compared with the following Healthcare names: